Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label investigator-led study being conducted in pediatric subjects Netherton Syndrome

Next Previous
Trial Profile

An open-label investigator-led study being conducted in pediatric subjects Netherton Syndrome

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QRX 003 (Primary)
  • Indications Netherton Syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 28 Oct 2025 According to a Quoin Pharmaceuticals media release, all three subjects will undergo twice-daily, whole-body application of QRX003 for an initial twelve-week period, after which they will continue treatment in a long-term extension protocol until regulatory approval is secured. Two subjects are based in Austria, and the third resides in Ireland.
  • 28 Oct 2025 Results published in a Quoin Pharmaceuticals media release
  • 28 Oct 2025 According to Quoin Pharmaceuticals media release, company today announced recruitment of three additional patients in investigator led pediatric Netherton Syndrome (NS) study as well as highly positive 9 month clinical data from the first pediatric patient in the study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top